|
1
|
Fang Y, Bao W, Rao Q, Wang X, Xia Q, Shen
Q, Zhou X and Yao B: TFE3 regulates renal adenocarcinoma cell
proliferation via activation of the mTOR pathway. Mol Med Rep.
16:2721–2725. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM,
Li Y, Nelson RA, Mu B, Onami SH, et al: Identification of a
4-microRNA signature for clear cell renal cell carcinoma metastasis
and prognosis. PLoS One. 7:e356612012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Russo P: Renal cell carcinoma:
Presentation, staging, and surgical treatment. Semin Oncol.
27:160–176. 2000.PubMed/NCBI
|
|
4
|
Papaioannou VE: The T-box gene family:
Emerging roles in development, stem cells and cancer. Development.
141:3819–3833. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ito A, Asamoto M, Hokaiwado N, Takahashi S
and Shirai T: Tbx3 expression is related to apoptosis and cell
proliferation in rat bladder both hyperplastic epithelial cells and
carcinoma cells. Cancer Lett. 219:105–112. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ansari D, Rosendahl A, Elebro J and
Andersson R: Systematic review of immunohistochemical biomarkers to
identify prognostic subgroups of patients with pancreatic cancer.
Br J Surg. 98:1041–1055. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Boyd SC, Mijatov B, Pupo GM, Tran SL,
Gowrishankar K, Shaw HM, Goding CR, Scolyer RA, Mann GJ, Kefford
RF, et al: Oncogenic B-RAF(V600E) signaling induces the T-Box3
transcriptional repressor to repress E-cadherin and enhance
melanoma cell invasion. J Invest Dermatol. 133:1269–1277. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Esmailpour T, Shang X, Gulsen G,
Liu A and Huang T: TBX3 over-expression causes mammary gland
hyperplasia and increases mammary stem-like cells in an inducible
transgenic mouse model. BMC Dev Biol. 11:652011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu R, Yang A and Jin Y: Dual functions of
T-box 3 (Tbx3) in the control of self-renewal and extra embryonic
endoderm differentiation in mouse embryonic stem cells. J Biol
Chem. 286:8425–8436. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dhawan P, Singh AB, Ellis DL and Richmond
A: Constitutive activation of Akt/protein kinase B in melanoma
leads to up-regulation of nuclear factor-kappaB and tumor
progression. Cancer Res. 62:7335–7342. 2002.PubMed/NCBI
|
|
11
|
Renard CA, Labalette C, Armengol C, Cougot
D, Wei Y, Cairo S, Pineau P, Neuveut C, de Reynies A, Dejean A, et
al: Tbx3 is a downstream target of the Wnt/beta-catenin pathway and
a critical mediator of beta-catenin survival functions in liver
cancer. Cancer Res. 67:901–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yarosh W, Barrientos T, Esmailpour T, Lin
L, Carpenter PM, Osann K, Anton-Culver H and Huang T: TBX3 is
overexpressed in breast cancer and represses p14 ARF by interacting
with histone deacetylases. Cancer Res. 68:693–699. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang HC, Meng QC, Shan ZZ, Yuan Z and
Huang XY: Overexpression of Tbx3 predicts poor prognosis of
patients with resectable pancreatic carcinoma. Asian Pac J Cancer
Prev. 16:1397–1401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shan ZZ, Yan XB, Yan LL, Tian Y, Meng QC,
Qiu WW, Zhang Z and Jin ZM: Overexpression of Tbx3 is correlated
with epithelial-mesenchymal transition phenotype and predicts poor
prognosis of colorectal cancer. Am J Cancer Res. 5:344–353.
2015.PubMed/NCBI
|
|
15
|
Redmond KL, Crawford NT, Farmer H, D'Costa
ZC, O'Brien GJ, Buckley NE, Kennedy RD, Johnston PG, Harkin DP and
Mullan PB: T-box 2 represses NDRG1 through an EGR1-dependent
mechanism to drive the proliferation of breast cancer cells.
Oncogene. 29:3252–3262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen J, Lu J, Sui L, Wang D, Yin M,
Hoffmann I, Legler A and Pflugfelder GO: The orthologous Tbx
transcription factors Omb and TBX2 induce epithelial cell migration
and extrusion in vivo without involvement of matrix
metalloproteinases. Oncotarget. 5:11998–12015. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fischer K and Pflugfelder GO: Putative
breast cancer driver mutations in TBX3 cause impaired
transcriptional repression. Front Oncol. 5:2442015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Smith J, Mowla S and Prince S: Basal
transcription of the human TBX3 gene, a key developmental regulator
which is overexpressed in several cancers, requires functional NF-Y
and Sp1 sites. Gene. 486:41–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Capparelli C, Chiavarina B,
Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, Andò S, Howell
A, Martinez-Outschoorn UE, Sotgia F, et al: CDK inhibitors
(p16/p19/p21) induce senescence and autophagy in cancer-associated
fibroblasts, ‘fueling’ tumor growth via paracrine interactions,
without an increase in neo-angiogenesis. Cell Cycle. 11:3599–3610.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Li B, Xu B, Han B, Xia H, Chen QM
and Li LJ: Expression of p53, p21(CIP1/WAF1) and eIF4E in the
adjacent tissues of oral squamous cell carcinoma: Establishing the
molecular boundary and a cancer progression model. Int J Oral Sci.
7:161–168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Varelas X, Bouchie MP and Kukuruzinska MA:
Protein N-glycosylation in oral cancer: Dysregulated cellular
networks among DPAGT1, E-cadherin adhesion and canonical Wnt
signaling. Glycobiology. 24:579–591. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li J, Weinberg MS, Zerbini L and Prince S:
The oncogenic TBX3 is a downstream target and mediator of the
TGF-β1 signaling pathway. Mol Biol Cell. 24:3569–3576. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Peters U, Jiao S, Schumacher FR, Hutter
CM, Aragaki AK, Baron JA, Berndt SI, Bézieau S, Brenner H,
Butterbach K, et al: Colon Cancer Family Registry and the Genetics
and Epidemiology of Colorectal Cancer Consortium: Identification of
genetic susceptibility loci for colorectal tumors in a Genome-Wide
meta-analysis. Gastroenterology. 144:799–807.e24. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peres J, Davis E, Mowla S, Bennett DC, Li
JA, Wansleben S and Prince S: The highly homologous T-Box
transcription factors, TBX2 and TBX3, have distinct roles in the
oncogenic process. Genes Cancer. 1:272–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Ballim D, Rodriguez M, Cui R, Goding
CR, Teng H and Prince S: The anti-proliferative function of the
TGF-β1 signaling pathway involves the repression of the oncogenic
TBX2 by its homologue TBX3. J Biol Chem. 289:35633–35643. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Walker AS, Johnson EK, Maykel JA,
Stojadinovic A, Nissan A, Brucher B, Champagne BJ and Steele SR:
Future directions for the early detection of colorectal cancer
recurrence. J Cancer. 5:272–280. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang HC, Meng QC, Shan ZZ, Yuan Z and
Huang XY: Overexpression of Tbx3 predicts poor prognosis of
patients with resectable pancreatic carcinoma. Asian Pac J Cancer
Prev. 16:1397–1401. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shan ZZ, Yan XB, Yan LL, Tian Y, Meng QC,
Qiu WW, Zhang Z and Jin ZM: Overexpression of Tbx3 is correlated
with Epithelial-Mesenchymal Transition phenotype and predicts poor
prognosis of colorectal cancer. Am J Cancer Res. 5:344–353.
2014.PubMed/NCBI
|
